# NOVARTIS: SI Lobbying | SI Money Map

> NOVARTIS: $14.0M disclosed on 7 lobbying reports that name SI issues, Q1 2025 to Q3 2026. Every filing linked, from LDA.gov. Free to cite. Free to cite.

Source: https://tsio.si/money-map/novartis/
Updated: 2026-11-19
Publisher: The SI Observatory (tsio.si), run by the SI community, built by Codeflex

1. [Home](https://tsio.si/)
2. [SI Money Map](https://tsio.si/money-map/)
3. NOVARTIS

SI Money Map · Client

# NOVARTIS and SI policy

**NOVARTIS is the client on 7 federal lobbying reports that name SI issues, Q1 2025 to Q3 2026, disclosing $14.0M by the amount rule: $7.8M in 2025 and $6.2M in 2026 so far.** It filed 7 reports for itself. Rank 33 of 1,245 clients. Read from LDA.gov, Nov 17, 2026. Amounts are filing totals for all issues on each filing.

Updated **Nov 17, 2026** · Rank **33** · **7** SI filings

The filings

[Every company](https://tsio.si/money-map/#companies)

[Share on X](https://x.com/intent/post?text=NOVARTIS%3A+%2414.0M+disclosed+on+7+lobbying+reports+that+name+SI+issues.+From+LDA.gov%2C+on+the+SI+Money+Map%3A&url=https%3A%2F%2Ftsio.si%2Fmoney-map%2Fnovartis%2F)

- **Reported, all quarters**: $14.0M
- **SI filings**: 7
- **Quarters with filings**: 7
- **Lobbyist IDs on SI**: 9

Over time

## Quarter by quarter

Q1 2025 to Q3 2026. Q3 2026 reports were due Oct 20, 2026.

*Chart: NOVARTIS: reported amount by quarter. By the amount rule: the in-house report when there is one, else the outside firms' reports.*

| Quarter | Filings | In-house | Outside firms | Counted |
|---|---|---|---|---|
| Q3 2026 | 1 | $840,000 | none | **$840,000** |
| Q2 2026 | 1 | $1,410,000 | none | **$1,410,000** |
| Q1 2026 | 1 | $3,930,000 | none | **$3,930,000** |
| Q4 2025 | 1 | $1,000,000 | none | **$1,000,000** |
| Q3 2025 | 1 | $1,700,000 | none | **$1,700,000** |
| Q2 2025 | 1 | $920,000 | none | **$920,000** |
| Q1 2025 | 1 | $4,168,000 | none | **$4,168,000** |

SI filings and amounts by quarter. Counted: the in-house amount when NOVARTIS filed an SI report for itself that quarter, otherwise the outside firms' amounts. Subcontracts are never added.

The filings

## Every SI filing for NOVARTIS

Each LD-2 report with at least one issue line that names SI, newest first, with the link to the filing on LDA.gov. "SI lines" shows how many of the filing's issue lines name SI.

| Quarter | Filed by | Amount | SI lines | Issue codes and bills | Source |
|---|---|---|---|---|---|
| Q3 2026Q3, posted Oct 20, 2026 | NOVARTISIn-house | $840,000 | 1 of 7 | Health IssuesH.R. 2214, H.R. 3037, H.R. 5256, H.R. 8800, H.R. 946, H.R. 9504, H.R. 9599, S. 1500 ... | [LDA.gov](https://lda.gov/filings/public/filing/d96e0348-ed45-43c9-86b7-6380c0dfcc90/print/) |
| Q2 2026Q2, posted Jul 20, 2026 | NOVARTISIn-house | $1,410,000 | 1 of 7 | Health IssuesH.R. 1262, H.R. 2214, H.R. 3037, H.R. 5256, H.R. 8800, H.R. 946, H.R. 9504, H.R. 9599 ... | [LDA.gov](https://lda.gov/filings/public/filing/cb76bfb5-8577-4487-a413-a9e8b217d053/print/) |
| Q1 2026Q1, posted Apr 20, 2026 | NOVARTISIn-house | $3,930,000 | 1 of 7 | Health IssuesH.R. 1262, H.R. 2214, H.R. 3037, H.R. 5256, H.R. 946, S. 1500, S. 1682, S. 864 ... | [LDA.gov](https://lda.gov/filings/public/filing/88a6ffbd-8400-46ef-af8c-de6159486b34/print/) |
| Q4 2025Q4, posted Jan 20, 2026 | NOVARTISIn-house | $1,000,000 | 1 of 7 | Health IssuesH.R. 1262, H.R. 2214, H.R. 3037, H.R. 5256, H.R. 946, S. 1500, S. 1682, S. 864 ... | [LDA.gov](https://lda.gov/filings/public/filing/110e01d6-c828-411f-b542-ef89cf18779e/print/) |
| Q3 20253A, posted Mar 9, 2026 | NOVARTISIn-house | $1,700,000 | 1 of 7 | Health IssuesH.R. 1262, H.R. 2214, H.R. 3037, H.R. 5256, H.R. 946, S. 1500, S. 864, S. 932 | [LDA.gov](https://lda.gov/filings/public/filing/7b1318c9-2b05-4242-8cd8-d25510672fe4/print/) |
| Q2 20252A, posted Mar 9, 2026 | NOVARTISIn-house | $920,000 | 1 of 7 | Health IssuesH.R. 1262, H.R. 2214, H.R. 3037, H.R. 946, S. 1500, S. 864 | [LDA.gov](https://lda.gov/filings/public/filing/fb83c94e-6544-4804-9a49-55a037767b57/print/) |
| Q1 2025Q1, posted Apr 21, 2025 | NOVARTISIn-house | $4,168,000 | 1 of 7 | Health IssuesH.R. 1262, H.R. 2214, H.R. 946, S. 864 | [LDA.gov](https://lda.gov/filings/public/filing/9f1ac4b8-2ac6-4260-a2bc-005a7fc5ac7c/print/) |

Amount: income reported by an outside firm, or expenses reported in-house, for all issues on the filing.

In their own words

## What the filings say

The SI issue lines, quoted as filed: newest first, repeats left out, long lines cut short. The words are the filers'; the filings are public records.

- **Names as filed**: NOVARTIS
- **Issue codes**: Health Issues (7)
- **Bills named**: H.R. 2214 (7), H.R. 946 (7), S. 864 (7), H.R. 1262 (6), H.R. 3037 (6), S. 1500 (6), H.R. 5256 (5), S. 932 (4), S. 1682 (4), H.R. 8800 (2), H.R. 9504 (2), H.R. 9599 (2)

1. Q3 2026 "Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net ..." Health Issues, filed by NOVARTIS. [The filing](https://lda.gov/filings/public/filing/d96e0348-ed45-43c9-86b7-6380c0dfcc90/print/)
2. Q3 2025 "340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend ..." Health Issues, filed by NOVARTIS. [The filing](https://lda.gov/filings/public/filing/7b1318c9-2b05-4242-8cd8-d25510672fe4/print/)
3. Q2 2025 "340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of ..." Health Issues, filed by NOVARTIS. [The filing](https://lda.gov/filings/public/filing/fb83c94e-6544-4804-9a49-55a037767b57/print/)

Embed

## Put this card on any page

A plain image that links back here, with its source printed on it. Free under CC BY 4.0. **Filings, not influence.** The SI Money Map shows what federal disclosure filings report: who paid for lobbying, which issues and bills the filings name, and what super PACs raised and spent. It does not show influence, intent or results, and it takes no side.

Copy the embed

```
<a href="https://tsio.si/money-map/novartis/"><img src="https://tsio.si/money-map/novartis/card.svg" width="480" height="240" alt="The SI Money Map: NOVARTIS, $14.0M reported on SI lobbying filings"></a>
```

![SI Money Map card for NOVARTIS](https://tsio.si/money-map/novartis/card.svg)
